Does doxepin increase the risk of falls?

Yes, doxepin can increase the risk of falls, though the evidence suggests this risk is lower compared to other psychotropic medications, particularly benzodiazepines and higher-dose tricyclic antidepressants.

Evidence from Guidelines and Drug Labels

The 2001 American Geriatrics Society Guidelines on Falls Prevention clearly establish that psychotropic medications carry an odds ratio of 1.7 for falls 1. While these guidelines do not specifically isolate doxepin, they emphasize that patients taking four or more medications and those on psychotropic medications (including antidepressants) should have their medications reviewed and reduced when possible to minimize fall risk 1.

The FDA drug label for doxepin does not explicitly list falls as an adverse effect, but it does note anticholinergic effects, drowsiness, and orthostatic hypotension—all of which are established fall risk factors 2. The label specifically advises careful dose adjustment in geriatric patients.

Critical Distinction: Low-Dose vs. Standard-Dose Doxepin

The most important clinical consideration is the dose of doxepin being used:

• Low-dose doxepin (3-6 mg) for insomnia: The 2020 VA/DoD Clinical Practice Guidelines note that low-dose doxepin showed no significant differences in adverse event rates compared to placebo in clinical trials, though the risk for suicidal ideation cannot be excluded 3. A 2017 randomized controlled trial directly comparing doxepin 6 mg to zolpidem 10 mg found that doxepin had significantly lower fall risk and better arousability compared to zolpidem, with fall risk not differing significantly from placebo 4.

• Standard antidepressant doses (≥25 mg): At these doses, doxepin functions as a tricyclic antidepressant with more pronounced anticholinergic and sedating effects, which would be expected to increase fall risk more substantially.

Clinical Algorithm for Fall Risk Assessment with Doxepin

When evaluating fall risk in patients on doxepin:

1. Determine the dose: Low-dose (≤10 mg) carries lower risk than standard antidepressant doses
2. Count total medications: Polypharmacy (≥4 medications) independently increases fall risk (OR 2.6) 1
3. Assess for drug-drug interactions: Particularly with other CNS-active medications or CYP2D6 inhibitors that increase doxepin levels 2
4. Evaluate intrinsic fall risk factors: History of falls (OR 3.0), muscle weakness (OR 4.4), gait/balance deficits (OR 2.9), visual deficits (OR 2.5), and age >80 years (OR 1.7) 1
5. Monitor for orthostatic hypotension and sedation: These are the primary mechanisms by which doxepin increases fall risk

Comparative Risk Context

Doxepin appears to carry lower fall risk than several alternatives:

• Benzodiazepines (midazolam, lorazepam) are explicitly noted to have "increased risk of falls" in the 2018 ESMO guidelines 5
• Zolpidem showed significantly higher fall risk than low-dose doxepin in head-to-head comparison 4
• A 2009 study found zolpidem (AOR 2.59) and meprobamate (AOR 3.01) significantly increased fall risk in hospitalized elderly, though doxepin was not specifically studied 6

Common Pitfalls to Avoid

1. Don't assume all doses carry equal risk: Low-dose doxepin for insomnia has a different risk profile than antidepressant doses
2. Don't overlook drug interactions: CYP2D6 inhibitors (SSRIs, quinidine) can substantially increase doxepin levels and associated risks 2
3. Don't use in isolation: Fall risk assessment must include all medications and intrinsic patient factors
4. Don't ignore the cumulative effect: The combination of doxepin with other CNS-active drugs dramatically increases risk

Practical Recommendation

If prescribing doxepin in patients at risk for falls, use the lowest effective dose (3-6 mg for insomnia), avoid concurrent benzodiazepines or other sedating medications, ensure adequate time for dose titration, and implement fall prevention strategies including environmental modifications and balance training 1, 3, 1. In patients with multiple fall risk factors or history of falls, consider non-pharmacologic interventions first, as the 2019 AGS Beers Criteria emphasizes caution with all psychotropic medications in older adults 7.